Measuring the Cost-Effectiveness of Cancer Care
June 1st 1996This timely and informative review describes the components of a cost-effectiveness analysis and provides useful commentary on various ways to measure them. It may be helpful, however, to take a step back and compare cost-effectiveness analysis to the other basic approaches to economic analysis.
Measuring the Cost-Effectiveness of Cancer Care
June 1st 1996The failure to contain health-care costs and curtail growth is a growing national economic concern and public policy issue. The marketplace is rapidly changing how health care is paid for by moving from fee-for-service mechanisms to prospective payment, diagnosis-related groups, and increasing exclusion of some treatment(s).
Measuring the Cost-Effectiveness of Cancer Care
June 1st 1996Historically, new therapeutic strategies for cancer have been evaluated on the basis of safety and clinical efficacy. However, the current national emphasis on efficiency of resource allocation has led to the inclusion of economic assessments in oncology studies. Economic assessments measure patients' health status and resource consumption associated with a therapeutic strategy, and combine these in a cost-effectiveness analysis. Study design can include prospective analysis of clinical trials, retrospective analysis of a clinical trial or administrative databases, or a decision analytic model. Economic analysis is being used increasingly in oncology and will continue to provide meaningful data to assist clinicians in determining the optimal treatment strategies for cancer patients and to help inform health policy decision-makers about the importance of specific cancer therapeutic strategies. [ONCOLOGY 9(6):523-538, 1995]
MRI May Reduce the Number of Biopsies for Breast Cancer
June 1st 1995Like a colorblind coach who can see all the players but cannot tell who is friendly, x-ray mammography is effective in finding suspicious breast lesions but is not reliable in determining which ones are cancerous. Because of this uncertainty, about
Equal Treatment Means Similar Survival for Esophageal Cancer Patients, Regardless of Race
June 1st 1995African-Americans and Caucasians who have the same type of esophageal cancer and receive the same quality of treatment have a similar survival rate, preliminary results of a national study show.
Book Review: Adjuvant Therapy of Cancer--VII
June 1st 1995This is the seventh in a well-known series of conference summaries, organized and edited by Dr. Salmon. A perusal of the contents of these volumes over the past two decades reveals the evolution of concepts related to combined-modality therapy
Ultrasound Guided Fine-Needle Aspiration Biopsy Proves 100% Accurate in 166 Women
June 1st 1995A study of 166 women with suspicious mammograms who underwent ultrasound-guided fine-needle aspiration cytology (USFNAC) showed the technique to be 100% accurate in diagnosing cancers, reported Dr. Thomas G. Frazier at the annual
New Approach to Diagnosing High-Risk, Early-Stage Ovarian Cancer
June 1st 1995Swedish researchers have, for the first time, used a combination of methods to accurately diagnose high-risk patents with early-stage ovarian cancer, thereby identifying those who would benefit from more aggressive treatment.
New Jersey Researchers Testing Unique Blood Substitute
June 1st 1995A new blood substitute with broad life-saving potential is being tested at the University of Medicine and Dentistry of New Jersey (UMDNJ). The unique blood product is made with a patented chemical modification process developed by Enzon
Freezing Shows Promise in Treating Prostate Cancer
June 1st 1995By literally freezing prostate cancer cells to death, radiologists can effectively treat prostate cancer in some patients while reducing complication rates, preliminary results of a study show. The new procedure, trans- rectal ultrasound-guided
Vinorelbine/Paclitaxel Combination Studied in Treatment of Metastatic Breast Cancer Patients
June 1st 1995The combination of vinorelbine tartrate (Navelbine) and paclitaxel (Taxol) appears promising for the treatment of patients with metastatic breast cancer, including some patients who had previously receivedanthracycline-based adjuvant therapy,
Equal Treatment Means Equal Survival for African-Americans With Prostate Cancer
June 1st 1995African-American men with prostate cancer live as long as their white counterparts if they receive the same treatment, two cancer research studies show. African-American men, however, are not receiving comparable treatment, says Dr. Mack
Lifestyle, Not Race, Plays Major Role in Lung Cancer Survival
June 1st 1995Race does not play a stastically significant role in lung cancer patients'survival, a recent analysis shows. Instead, cigarette use, stage of disease, and other factors appear to be reasons more African-Americans die of lung cancer than their Caucasian
Indicators of Nicotine Addiction Among Women-United States, 1991 to 1992
June 1st 1995An estimated 22 million US women were current smokers in 1993; of these, 73% wanted to quit smoking [1]. However, attempts to quit smoking and to remain abstinent are hindered by nicotine addiction and by the subsequent effects of nicotine
PSA-Based Diagnoses Are Leading to Improved Prostate Cancer Outcomes
June 1st 1995Prostate-specific antigen (PSA) testing has changed the face of prostate cancer, leading to earlier diagnosis and improved outcome, says David F. Paulson, md, professor and chairman, Division of Urology, Duke University Medical School.
Invasive Radiologic Procedures Pose Low Risk of HIV Transmission From Doctor to Patient
June 1st 1995The estimated risk of HIV transmission from doctor to patient during an invasive radiologic procedure is quite low, slightly less than the risk during surgery, according to a study from the University of Texas Southwestern Medical Center at Dallas
Integration of Vinorelbine into Chemotherapy Strategies for Non-Small-Cell Lung Cancer
June 1st 1995Meta-analyses of randomized clinical studies comparing combination chemotherapy versus "best supportive care" for advanced non-small-cell lung cancer have revealed a small, but statistically significant survival
Management of Malignant Biliary Obstruction: Nonoperative and Palliative Techniques
June 1st 1995Biliary tract drainage, with or without placement of an endoprosthesis, is used as a palliative therapy for malignant biliary obstruction. The first truly internal endoprostheses represented a distinct improvement over internal-external catheters but still remained patent for only 4 to 6 months. Metallic stents have a long-term patency of 6 to 8 months. At present, it appears that patients with unresectable pancreatic cancer should be palliated with endoscopically placed plastic or metal stents, whereas those with malignant obstructions higher in the biliary tree are probably better managed with transhepatically placed stents. The combination of brachytherapy plus external-beam radiation followed by implantation of a Gianturco metal stent may be a viable approach to treating obstructions in patients with cholangiocarcinoma. For those with other noncholangiocarcinomas, particularly when life expectancy exceeds anticipated stent patency duration, the Wallstent may be the device of choice. [ONCOLOGY 9(6):493-504, 1995]
Current Concepts in Surgical Management of Neck Metastases from Head and Neck Cancer
May 31st 1995This article will address modified, selective, and radical neck dissection as well as other surgical considerations, and will review the surgical techniques currently available for neck treatment.